一 基本情况

黄守杰(Shou-Jie Huang)教授级高级工程师
中华预防医学疫苗临床研究专业委员会会员


二 学习经历
2008年 获厦门大学生物化学与分子生物学硕士学位
1999年 获北京大学公共卫生学院医学学士学位
三 工作经历
2020年 厦门大学公共卫生学院 教授级高级工程师
2012年 厦门大学公共卫生学院 高级实验师
2011年 厦门大学公共卫生学院 实验师
2004年 厦门大学医学院 实验师
1999年 厦门大学医学院 助理实验师


四 主要研究方向
疫苗临床试验、传染病流行病学
五 科研
2006年至今从事疫苗临床试验和传染病流行病学研究，在疫苗临床试验领域具有丰富的经验。作为主要研究成员完善和构建疫苗临床试验质量保证体系。开展了戊肝疫苗、双价HPV、九价HPV、7D水痘、新冠等17项疫苗临床试验。其中戊肝疫苗于2012年全球首个成功上市，双价HPV疫苗于2019年国产首个成功上市。主持或参与国家自然科学基金、国家传染病重大科技专项等10多个项目。已在NEJM、Lancet、IJC、CMI等学术刊物发表论文60余篇。先后获得江苏省科学技术奖一等奖（2012年）、求是科技基金会杰出科技成就集体奖（2015年）等科研奖励。


代表性论文
1)Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans[J]. Nature communications, 2020, 11(1): 1-13.
2)Comparing Immunogenicity of the Escherichia coli-produced Bivalent Human Papillomavirus Vaccine in Females of Different Ages[J]. Vaccine, 2020, 38(39): 6096–6102.
3)Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals[J]. Human Vaccines & Immunotherapeutics, 2020, 16(7): 1630-1635.
4)Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China[J]. Annals of Oncology, 2019, 30(10): 1630-1637.
5)Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years[J]. Vaccine, 2019, 37(32): 4581-4586.
6)Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J]. Science China-Life Sciences, 2020, 63(4):582-591.

7)Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial[J]. Journal of the National Cancer Institute, 2020, 112(2): 145-153.

8)Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study[J]. Clinical Infectious Diseases, 2020, 70(1): 82-89.

9)Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study[J]. International journal of cancer. 2019, 145(3): 807-816.

10)Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial[J]. Clinical Microbiology and Infection, 2019, 25(9): 1133-1139.

11)The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: A population-based study[J]. International journal of cancer, 2018, 142(6): 1244-1251.

12)Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system[J]. Emerging Microbes & Infections, 2017, 6(1): 1-8.

13)Persistence of antibodies acquired by natural hepatitis E virus infection and the effects of vaccination [J]. Clinical Microbiology and Infection, 2017, 23 (5): 336.e1-336.e4.

14)Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study [J]. Emerging Microbes & Infections, 2016, 5(1): 1-8.

15)Immunogenicity and safety of an E. coli–produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial [J]. Vaccine, 2015, 33(32): 3940-3946.

16)Long-term efficacy of a hepatitis E vaccine [J]. New England Journal of Medicine, 2015, 372(10): 914-922.

17)Protective immunity against HEV [J]. Current opinion in virology, 2014, 5(1): 1-6.

18)Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-label phase I clinical trial [J]. Human vaccines & immunotherapeutics, 2014, 10(2): 469-475.

19)Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity [J]. Clinical Microbiology and Infection, 2014, 20(6): O397-O405.

20)Profile of acute infectious markers in sporadic hepatitis E [J]. PloS one, 2010, 5(10): e13560.

21)Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial [J]. Lancet, 2010, 376(9744): 895-902.